Tocagen On The Rocks With Phase III Brain Cancer Study Failure

 
• By Joseph Haas

The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or meet any secondary endpoints in a Phase III study in recurrent high-grade glioma.

male doctor in studio, thumbs down, showing failed, bad news - Image
Tocagen's TOCA 5 trial missed the primary, all secondary endpoints

More from Clinical Trials

More from R&D